<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0311211256
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DICERAN 16 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CANDESARTAN CILEXETIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        28.3
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Novartis Pharmaceutical Manufacturing LLC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Novartis Pharmaceutical Manufacturing LLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The name of your medicine is Dicran. The active substance is candesartan cilexetil. This belongs to a group of medicines called angiotensin II receptor antagonists. It works by making your blood vessels relax and widen. This helps to lower your blood pressure. It also makes it easier for your heart to pump blood to all parts of your body.</p><p>This medicine is used to:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat high blood pressure (hypertension) in adult patients and in children and adolescents aged 6 to</p><p>&lt;18 years.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat adult heart failure patients with reduced heart muscle function when Angiotensin Converting Enzyme (ACE) inhibitors cannot be used or in addition to ACE-inhibitors when symptoms persist despite treatment and mineralocorticoid receptor antagonists (MRA) cannot be used. (ACE- inhibitors and MRAs are medicines used to treat heart failure).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp; Do not take Dicran</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to candesartan cilexetil or to any of the ingredients of this medicine listed in section 6.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are more than 3 months pregnant. (it is also better to avoid Dicran in early pregnancy &ndash; see pregnancy section).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver disease or biliary obstruction (a problem with the drainage of the bile from the gall bladder).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the patient is a child under 1 year of age.</p><p>&nbsp;</p><p>If you are not sure if any of these apply to you, talk to your doctor or pharmacist before taking Dicran.</p><p>Warnings and precautions</p><p><strong>Talk to your doctor or pharmacist before taking Dicran</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have heart, liver or kidney problems, or are on dialysis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have recently had a kidney transplant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are vomiting, have recently had severe vomiting, or have diarrhoea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a disease of the adrenal gland called Conn&rsquo;s syndrome (also called primary hyperaldosteronism).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have low blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had a stroke.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking any of the following medicines used to treat high blood pressure:</p><p>-&nbsp; an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes- related kidney problems.</p><p>-&nbsp; aliskiren</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking an ACE-inhibitor together with a medicine which belongs to the class of medicines known as mineralocorticoid receptor antagonists (MRA). These medicines are for the treatment of heart failure (see &ldquo;Other medicines and Dicran&rdquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you must tell your doctor if you think you are (<u>or might become</u>) pregnant. Dicran is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</p><p>&nbsp;</p><p>&nbsp;</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p>See also information under the heading &ldquo;Do not take Dicran&rdquo;</p><p>Your doctor may want to see you more often and do some tests if you have any of these conditions</p><p>If you are going to have an operation, tell your doctor or dentist that you are taking Dicran. This is because Dicran, when combined with some anaesthetics, may cause an excessive drop in blood pressure.</p><p>Children and adolescents</p><p>Candesartan cilexetil has been studied in children. For more information, talk to your doctor. Dicran must not be given to children under 1 year of age due to the potential risk to the developing kidneys.</p><p>Other medicines and Dicran</p><p><strong>Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.</strong></p><p>Dicran can affect the way some other medicines work and some medicines can have an effect on Dicran. If you are using certain medicines, your doctor may need to do blood tests from time to time.</p><p>In particular, tell your doctor if you are using any of the following medicines as your doctor may need to change your dose and/or take other precautions:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines to help lower your blood pressure, including beta-blockers, diazoxide and ACE- inhibitors such as enalapril, captopril, lisinopril or ramipril.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, diclofenac, celecoxib or etoricoxib (medicines to relieve pain and inflammation).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acetylsalicylic acid (if you are taking more than 3 g each day) (medicine to relieve pain and inflammation).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Potassium supplements or salt substitutes containing potassium (medicines that increase the amount of potassium in your blood).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heparin (a medicine for thinning the blood).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Co-trimoxazole (an antibiotic medicine) also known as trimethoprim/sulfamethoxazole.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Water tablets (diuretics).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lithium (a medicine for mental health problems).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking an ACE-inhibitor or aliskiren (see also information under the headings &ldquo;Do not take Dicran&rdquo; and &ldquo;Warnings and precautions&rdquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are being treated with an ACE-inhibitor together with certain other medicines to treat your heart failure, which are known as mineralocorticoid receptor antagonists (MRA) (for example spironolactone, eplerenone).</p><p>Dicran with food, drink and alcohol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take Dicran with or without food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When you are prescribed Dicran, discuss with your doctor before drinking alcohol. Alcohol may make you feel faint or dizzy.</p><p>Pregnancy and breast-feeding</p><p><u>Pregnancy</u></p><p>You must tell your doctor if you think you are (<u>or might becom</u>e) pregnant. Your doctor will normally advise you to stop taking Dicran before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Dicran. Dicran is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p><u>Breast-feeding</u></p><p>Tell your doctor if you are breast-feeding or about to start breast-feeding. Dicran is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p>Driving and using machines</p><p>Some people may feel tired or dizzy when taking Dicran. If this happens to you, do not drive or use any tools or machines.</p><p>Dicran contains lactose</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>Dicran contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &ldquo;sodium- free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. It is important to keep taking Dicran every day.</p><p>You can take Dicran with or without food. Swallow the tablet with a drink of water.</p><p>Try to take the tablet at the same time each day. This will help you to remember to take it. Dividing the tablets:</p><p>If necessary, the tablet can be divided into equal doses. Put the tablet with the score line facing up onto a hard smooth surface (e.g. tabletop or plate). Place your index fingers (or thumbs) on either side of the</p><p>line and push simultaneously briefly and hard.</p><p>&nbsp;</p><p>High blood pressure:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose of [Dicran] is 8 mg once daily. Your doctor may increase this dose to 16 mg once a day and further up to 32 mg once a day depending on blood pressure response.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In some patients, such as those with liver problems, kidney problems or those who recently have lost body fluids, e.g., through vomiting or diarrhoea or by using water tablets, the doctor may prescribe a lower starting dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some black patients may have a reduced response to this type of medicine, when given as the only treatment, and these patients may need a higher dose.</p><p><em>Use in children and adolescents with high blood pressure:</em></p><p>Children 6 to &lt;18 years of age:</p><p>The recommended starting dose is 4 mg once daily.</p><p>For patients weighing &lt; 50 kg: In some patients whose blood pressure is not adequately controlled, your doctor may decide the dose needs to be increased to a maximum of 8 mg once daily.</p><p>For patients weighing &ge; 50 kg: In some patients whose blood pressure is not adequately controlled, your</p><p>doctor may decide the dose needs to be increased to 8 mg once daily and to 16 mg once daily. Heart failure:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended starting dose of [Dicran] is 4 mg once a day. Your doctor may increase your dose by doubling the dose at intervals of at least 2 weeks up to 32 mg once a day. Dicran can be taken together with other medicines for heart failure, and your doctor will decide which treatment is suitable for you.</p><p>If you take more Dicran than you should</p><p>If you take more Dicran than prescribed by your doctor, contact a doctor or pharmacist immediately for advice.</p><p>If you forget to take Dicran</p><p>Do not take a double dose to make up for a forgotten tablet. Just take the next dose as normal.</p><p>If you stop taking Dicran</p><p>If you stop taking Dicran, your blood pressure may increase again. Therefore do not stop taking Dicran without first talking to your doctor.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. It is important that you are aware of what these side effects may be.</p><p>Stop taking Dicran and seek medical help immediately if you have any of the following allergic reactions:</p><p>&bull;&nbsp; difficulties in breathing, with or without swelling of the face, lips, tongue and/or throat</p><p>&bull;&nbsp; swelling of the face, lips, tongue and/or throat, which may cause difficulties in swallowing</p><p>&bull;&nbsp; severe itching of the skin (with raised lumps)</p><p>Dicran may cause a reduction in number of white blood cells. Your resistance to infection may be decreased and you may notice tiredness, an infection or a fever. If this happens contact your doctor. Your doctor may occasionally do blood tests to check whether Dicran has had any effect on your blood (agranulocytosis).</p><p>Other possible side effects include:</p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling dizzy/spinning sensation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respiratory infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure. This may make you feel faint or dizzy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in blood test results:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increased amount of potassium in your blood, especially if you already have kidney problems or heart failure. If this is severe you may notice tiredness, weakness, irregular heart beat or pins and needles.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effects on how your kidneys work, especially if you already have kidney problems or heart failure. In very rare cases, kidney failure may occur.</p><p><strong>Very rare </strong>(may affect up to 1 in 10,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, lips, tongue and/or throat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A reduction in your red or white blood cells. You may notice tiredness, an infection or a fever.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash, lumpy rash (hives).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Back pain, pain in joints and muscles.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in how your liver is working, including inflammation of the liver (hepatitis). You may notice tiredness, yellowing of your skin and the whites of your eyes and flu like symptoms.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in blood test results:</p><p>-&nbsp; A reduced amount of sodium in your blood. If this is severe then you may notice</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weakness, lack of energy, or muscle cramps.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough.</p><p><strong>Not known </strong>(frequency cannot be estimated from the available data)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea.</p><p>&nbsp;</p><p>&nbsp;</p><p>Additional side effects in children and adolescents</p><p>In children treated for high blood pressure, side effects appear to be similar to those seen in adults, but they happen more often. Sore throat is a very common side effect in children but not reported in adults and runny nose, fever and increased heart rate are common in children but not reported in adults.</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children. Store below 30˚ C.</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Store in the original package in order to protect from moisture.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is candesartan cilexetil.</p><p>Each tablet contains 16 mg of candesartan cilexetil.</p><p>The other ingredients are lactose monohydrate, maize starch, povidone K30, carrageenan, croscarmellose sodium, magnesium stearate, ferric oxide, red (E 172) and titanium dioxide (E 171).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Tablet.
16 mg tablets: Pink, mottled, round biconvex tablet, debossed with 16 on one side and scored on the other side.
Pack sizes:
Al/Al Blister pack.
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Sandoz GmbH, 10, 6250 Kundl, Austria</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Lek Pharmaceuticals d.d.</p><p>Verov&scaron;kova 57, 1526 Ljubljana, Slovenia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                07/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">الدَّواء الخاص بك اسمه عقار ديسيران. المادة الفعالة هي كانديسارتان سيليكسيتيل. ينتمي إلى مجموعة من الأدوية تسمى مناهضات مستقبلات أنجيوتنسين-2. فهو يعمل على إرخاء الأوعية الدموية لديك وتوسيعها. ويُساعد ذلك على خفض ضغط الدَّم لديك. كما يُسَهِّل من عملية قيام القلب بضخ الدَّم إلى جميع أجزاء الجسم.</p><p dir="RTL">يُستخدم هذا الدَّواء في الآتي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج ارتفاع ضغط الدَّم في المرضى من البالغين والأطفال والمراهقين بعُمْر 6 إلى &lt; 18 عامًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج مرضى فشل القلب ممن لديهم قصور في وظائف عضلة القلب عندما يكون من غير المُمكِن استخدام مثبطات الإنْزيم المُحَوِّل للأَنْجيُوتَنْسينِ أو كعلاج إضافي إلى جانبها عندما تستمر الأعراض على الرغم من العلاج ويكون من غير المُمكِن استخدام مناهضات مستقبلات المينيرالوكورتيكويد. (مثبطات الإنْزيم المُحَوِّل للأَنْجيُوتَنْسينِ ومناهضات مستقبلات المينيرالوكورتيكويد هي أدوية تُستَخدَم لعلاج فشل القلب).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول عقار ديسيران في الحالات الآتية</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من حساسية تجاه كانديسارتان سيليكسيتيل أو أيٍّ من المكونات الأخرى بهذا الدَّواء المُدرجة في قسم 6.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تجاوز حملك الشهر الثالث. (من الأفضل أيضًا تجنُّب تناوُل عقار ديسيران في مراحل الحمل المبكرة - انظري قسم: &quot;الحمل&quot;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من مرض كبدي شديد أو انسداد القنوات الصفراوية (مشكلة في تصريف العصارة الصفراوية من المرارة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض السُّكَّري أو تُعاني من قصور بوظائف الكُلى ويتم علاجك بدواء خافض لضغط الدَّم يحتوي على أليسكيرين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان المريض طفلًا يقل عُمْره عن عام واحد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا بشأن ما إذا كان أي من هذه الحالات ينطبق عليك أم لا، فتحدث إلى طبيبك أو الصيدلي الخاص بك قبل تناوُل عقار ديسيران.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL"><strong>تحدث إلى طبيبك أو الصيدلي الخاص بك قبل تناول عقار ديسيران في الحالات الآتية</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل بالقلب، بالكبد أو بالكلى أو كنت تخضع للغسيل الكلوي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد خضعت مؤخرًا لعملية زراعة كُلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتقيأ أو عانيت مؤخرًا من حالة شديدة من التَّقيؤ أو كنت تُعاني من الإِسْهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُصابًا بمرض في الغدة الكظرية يُسمى متلازمة كون (يُسمى أيضًا فرط الألدوستيرونية الأولي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك انخفاض بضغط الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من قبل من سكتة دماغية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أيًّا من الأدوية الآتية التي تُستَخدَم لعلاج ارتفاع ضغط الدَّم:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; أحد مثبطات الإنْزيم المُحَوِّل للأَنْجيُوتَنْسينِ (على سبيل المثال: إنالابريل، ليزينوبريل، راميبريل)، لا سيَّما إذا كنت مُصابًا بمشاكل بالكُلى ذات صلة بمرض السُّكَّرِي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; أليسكيرين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أحد مثبطات الإنْزيم المُحَوِّل للأَنْجيُوتَنْسينِ جنبًا إلى جنب مع دواء ينتمي إلى فئة من الأدوية تُعرَف بمناهضات مستقبلات المينيرالوكورتيكويد. تُستَخدَم هذه الأدوية لعلاج فشل القلب (انظر &quot;تناوُل أدوية أخرى مع عقار ديسيران&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عليكِ إخبار طبيبكِ إذا كنتِ تعتقدين أنكِ حامل (أو قد تصبحين حاملًا). لا يُوصى بتناوُل عقار ديسيران في مراحل الحمل المبكرة، ويجب عدم تناوُله إذا تجاوز حملكِ الشهر الثالث؛ إذ قد يُلْحِق بطفلكِ ضررًا خطيرًا إذا تم استخدامه في هذه المرحلة (انظري قسم: &quot;الحمل&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يُجري لك طبيبك فحصًا لوظائف الكُلى وضغط الدَّم وكمية الكهارل (على سبيل المثال: البوتاسيوم) في دمك على فترات منتظمة.</p><p dir="RTL">انظر أيضًا المعلومات تحت عنوان: &quot;لا تتناول عقار ديسيران في الحالات الآتية&quot;.</p><p dir="RTL">قد يرغب طبيبك في رؤيتك بشكل أكثر تكرارًا وإجراء بعض الاختبارات إذا أُصِبت بأي من هذه الحالات.</p><p>&nbsp;</p><p dir="RTL">إذا كنت ستخضع لعملية جراحية، فأخبِر طبيبك أو طبيب الأسنان الخاص بك أنك تتناول عقار ديسيران. ذلك لأنه عند استخدام عقار ديسيران بمصاحبة بعض أدوية التخدير فقد يؤدي إلى هبوط مفرط في ضغط الدَّم.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لم تتم دراسة كانديسارتان سيليكسيتيل في الأطفال. للحصول على مزيد من المعلومات، تحدث مع طبيبك. لا يجب إعطاء عقار ديسيران للأطفال دون سن&nbsp;عام واحد بسبب الخطورة المُحتَمَلة على نمو الكلى.</p><p dir="RTL"><strong>استخدام أدوية أخرى مع عقار ديسيران</strong></p><p dir="RTL"><strong>يُرجى إخبار طبيبك أو الصيدلي الخاص بك إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أيَّة أدوية أخرى</strong><strong>.</strong></p><p dir="RTL">قد يؤثر عقار ديسيران على طريقة عمل بعض الأدوية الأخرى وقد تؤثر بعض الأدوية على عقار ديسيران. إذا كنت تستخدم أدوية مُعيَّنة، فقد يحتاج طبيبك إلى إجراء اختبارات بالدَّم من آن إلى آخر.</p><p dir="RTL">على وجه الخصوص، أخبِر طبيبك إذا كنت تستخدم أيًّا من الأدوية التَّالية؛ إذ قد يحتاج طبيبك إلى تغيير جرعتك و/ أو اتخاذ احتياطات أخرى:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى تساعد على خفض ضغط الدَّم لديك، بما في ذلك حاصرات بيتا، الأدوية التي تحتوي على ديازوكسيد ومثبطات الإنزيم المحول للأنجيوتنسين مثل إنالابريل أو كابْتُوبْرِيل أو ليزينوبريل أو راميبريل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الالتهاب غير الستيرويدية مثل إيبوبروفين أو نابروكسين أو ديكلوفيناك أو سيليكوكسيب أو إتوريكوكسيب (أدوية لتخفيف الألم والالتهاب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمض أسيتيل الساليسيليك (إذا كنت تتناول أكثر من 3 جرامات كل يوم) (دواء لتخفيف الألم والالتهاب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكملات البوتاسيوم أو بدائل الملح التي تحتوي على البوتاسيوم (أدوية تُزيد من كمية البوتاسيوم لديك في الدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هيبارين (دواء يُستَخدَم لتسييل الدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كوترايموكسازول (مضاد حيوي)، ويُعرَف أيضًا باسم ترايميثوبريم/سلفاميثوكسازول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص الماء (مُدِرات البول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم (دواء يُستَخدَم لعلاج مشاكل الصحة النفسية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أحد مثبطات الإنْزيم المُحَوِّل للأَنْجيُوتَنْسينِ أو أليسكيرين (انظر أيضًا المعلومات الواردة أسفل العناوين: &quot;لا تتناول عقار ديسيران في الحالات الآتية&quot;، و&quot;تحذيرات واحتياطات&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع للعلاج بأحد مثبطات الإنْزيم المُحَوِّل للأَنْجيُوتَنْسينِ جنبًا إلى جنب مع أدوية أخرى لعلاج فشل القلب، والتي تُعرَف باسم مناهضات مستقبلات المينيرالوكورتيكويد (على سبيل المثال: سبيرونولاكتون أو إبليرينون).</p><p dir="RTL"><strong>استخدام عقار ديسيران مع الأطعمة والمشروبات والكحوليات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناول عقار ديسيران مع الطعام أو دونه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عندما يُوصَف لك عقار ديسيران، أجر مناقشة مع طبيبك قبل قيامك بشرب الكحوليات. قد يجعلك شرب الكحوليات تشعر بالإغماء أو الدوخة.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">يجب عليكِ إخبار طبيبكِ إذا كنتِ تعتقدين أنكِ حامل (أو قد تصبحين حاملًا). سينصحكِ طبيبكِ عادةً بالتَّوقُّف عن تناوُل عقار ديسيران قبل أن تُصبِحي حاملًا، أَو بِمجرّد أَن تعلمي أنكِ حامل، وسينصحكِ بِتناوُل دواء آخر بدلًا من عقار ديسيران. لا يُوصى باستخدام عقار ديسيران في مراحل الحمل المبكرة، ويجب ألا يتم تناوُله إذا تجاوز حملكِ الشهر الثالث؛ حيث إنه قد يُسبب أضرارًا خطيرة لطفلك إذا تم استخدامه بعد الشهر الثالث من الحمل.</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">أخبري طبيبك إذا كنتِ تُرضعين طفلكِ طبيعيًّا، أو على وشك البدء في إرضاعه طبيعيًّا. لا يُوصى باستخدام عقار ديسيران من قِبَل الأمهات اللاتي يمارسن الرضاعة الطبيعية، وقد يختار لكِ طبيبك علاجًا آخر إذا كنتِ ترغبين في الإرضاع، خاصةً إذا كان طفلكِ حديث الولادة، أو مبتسرًا.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يشعر بعض الأشخاص بالتعب أو الدوخة عند تناوُل عقار ديسيران. إذا حدث لك هذا، لا تمارس القيادة أو تستخدم أية أدوات أو آلات.</p><p dir="RTL"><strong>يحتوي عقار ديسيران على اللاكتوز</strong></p><p dir="RTL">إذا كان طبيبك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات، فاتصل به قبل تناول هذا الدَّواء.</p><p dir="RTL"><strong>يحتوي عقار ديسيران على الصوديوم</strong></p><p>يحتوي هذا الدَّواء على أقل من 1 مللي مول من الصوديوم (23 مجم) في كل قرص، وهو ما يعني أنه &quot;خال من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام. من المُهِم مواصلة تناوُل عقار ديسيران كل يوم.</p><p dir="RTL">يمكنك تناول عقار ديسيران مع الطعام أو دونه. ابتلع القرص مع كوب من الماء.</p><p dir="RTL">حاول تناوُل القرص في الوقت نفسه من كل يوم. سيُساعدك هذا على تذكر تناوُله.</p><p dir="RTL">تقسيم الأقراص:</p><p dir="RTL">إذا لزم الأمر، يُمكِن تقسيم القرص إلى جرعات متساوية. ضع القرص على سطح صلب وأملس (على سبيل المثال: طاولة أو طبق) مع جعل الوجه الذي يظهر عليه خط التَّقسيم لأعلى. ضع إصبعي السبابة (أو الإبهام) على أيٍّ من جانبي خط التَّقسيم وادفع بقوة ولفترة وجيزة في الوقت نفسه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ارتفاع ضغط الدَّم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المُوصى بها من عقار ديسيران هي 8 مجم مرَّة واحدة يوميًّا. قد يُزيد طبيبك هذه الجرعة إلى 16 مجم مرة واحدة يوميًّا وأكثر من ذلك حتى 32 مجم مرة واحدة يوميًّا حسب استجابة ضغط الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في بعض المرضى، مثل أولئك الذين يُعانون من مشاكل في الكبد أو مشاكل في الكُلى أو أولئك الذين فقدوا سوائل الجسم مؤخرًا، على سبيل المثال، من خلال القيء أو الإسهال أو عن طريق استخدام أقراص الماء، فقد يصف الطبيب جرعة بدء أقل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يكون لدى بعض المرضى من ذوي البشرة السمراء استجابة منخفضة لهذا النوع من الدَّواء، عند إعطائه كعلاج وحيد، وقد يحتاج هؤلاء المرضى إلى جرعة أعلى.</p><p dir="RTL"><em>الاستعمال في الأطفال والمراهقين ممن يعانون من ارتفاع ضغط الدم</em><em>:</em></p><p dir="RTL">الأطفال من عُمْر 6 سنوات إلى &lt;18 سنة:</p><p dir="RTL">جرعة البدء المُوصى بها هي 4 مجم مرة واحدة يوميًّا.</p><p dir="RTL">المرضى ممن تقل أوزانهم عن 50 كجم: في بعض المرضى الذين لا يتم التحكُّم في ضغط الدَّم لديهم بشكلٍ كافٍ، فقد يقرر الطبيب أن الأمر يستلزم زيادة الجرعة إلى 8 مجم مرَّة واحدة يوميًّا بحد أقصى.</p><p dir="RTL">المرضى ممن تبلغ أوزانهم 50 كجم أو تزيد: في بعض المرضى الذين لا يتم التحكُّم في ضغط الدَّم لديهم بشكلٍ كافٍ، فقد يقرر الطبيب أن الأمر يستلزم زيادة الجرعة إلى 8 مجم مرَّة واحدة يوميًّا و16 مجم مرَّة واحدة يوميًّا.</p><p dir="RTL">هبوط (فشل) القلب:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة البدء المُوصى بها من عقار ديسيران هي 4 مجم مرة واحدة يوميًّا. قد يُزيد طبيبك جرعتك عن طريق مضاعفة الجرعة على فواصل زمنية قدرها أسبوعان على الأقل حتى 32 مجم مرة واحدة يوميًّا. يُمكِن تناوُل عقار ديسيران بمصاحبة أدوية أخرى لعلاج فشل القلب، وسيقرر طبيبك ما العلاج المناسب لحالتك.</p><p dir="RTL"><strong>إذا تناولت كمية أكثر مما يجب من عقار ديسيران</strong></p><p dir="RTL">إذا تناولت كمية من عقار ديسيران أكثر من التي وصفها لك طبيبك، فاتصل بالطبيب أو الصيدلي فورًا للحصول على المشورة.</p><p dir="RTL"><strong>إذا أغفلت تناوُل عقار ديسيران</strong></p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض قرص أغفلته. تناوَل فقط الجرعة التالية كالمعتاد.</p><p dir="RTL"><strong>إذا توقفت عن تناوُل عقار ديسيران</strong></p><p dir="RTL">إذا توقفت عن تناوُل عقار ديسيران، فقد يرتفع ضغط الدَّم لديك مرّة أخرى. لذا لا تتوقف عن تناوُل عقار ديسيران بدون التحدُّث إلى طبيبك أولًا.</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع. من المُهِم أن تُدرِك ماهية هذه الآثار الجانبية.</p><p dir="RTL"><strong>توقف عن تناوُل عقار ديسيران واطلب المساعدة الطبية على الفور إذا أُصِبت بأي من تفاعلات الحساسية الآتية</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في التنفس، مصحوبة أو غير مصحوبة بتورم الوجه، الشفتين، اللسان و/ أو الحلق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، الشفتين، اللسان و/ أو الحلق، مما قد يسبب صعوبات في البلع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة شديدة بالجلد (مع وجود كتل بارزة).</p><p dir="RTL">&nbsp;قد يُسبب عقار ديسيران انخفاضًا في عدد خلايا الدَّم البيضاء. قد تنخفض مقاومتك للعدوى وقد تلاحظ حدوث تعب أو إصابة بعدوى أو حُمّى. إذا حدث ذلك فاتصل بطبيبك. قد يُجري لك طبيبك اختبارات بالدم في بعض الأحيان؛ للتحقق مما إذا كان لعقار ديسيران أي تأثير على دمك (ندرة خلايا المحببات) أم لا.</p><p dir="RTL">تشمل الآثار الجانبية المحتملة الأخرى ما يأتي:</p><p dir="RTL"><strong>شائعة </strong>(قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوخة/ الدوران.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بعدوى الجهاز التَّنفسي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدَّم. قد يجعلك ذلك تشعر بالإغماء أو الدوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث تغيُّرات في نتائج اختبارات الدَّم:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة كمية البوتاسيوم لديك في الدَّم، لا سيَّما إذا كنت مُصابًا بالفعل بمشاكل في الكُلى أو فشل القلب. إذا كانت هذه الحالة شديدة، فقد تلاحظ شعورك بالتعب أو الضعف أو عدم انتظام ضربات القلب أو وخز يشبه &quot;الإبر أو المسامير&quot;.</p><ul><li dir="RTL">تأثيرات على طريقة عمل الكُلى، لا سيَّما إذا كنت مُصابًا بمشاكل في الكُلى أو فشل القلب. في حالات نادرة جدًّا، لوحظ حدوث فشل كلوي.</li></ul><p dir="RTL"><strong>نادرة جدًّا</strong> (قد تؤثر على ما يصل إلى شخص واحد من بين كل 10000 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، الشفتين، اللسان و/ أو الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في خلايا الدَّم الحمراء أو البيضاء. قد تلاحظ حدوث تعب أو إصابة بعدوى أو حُمّى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، طفح جلدي مصحوب بظهور كتل (شرى [أرتكاريا]).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالظهر وألم في المفاصل والعضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّرات في طريقة عمل الكبد، يشمل ذلك التهاب الكبد. قد تلاحظ شعورك بالتعب واصفرار الجلد وبياض العينين وأعراضًا شبيهة بأعراض الأنفلونزا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث تغيُّرات في نتائج اختبارات الدَّم:</p><p dir="RTL">- انخفاض كمية الصوديوم لديك في الدَّم. إذا كانت هذه الحالة شديدة، فقد تلاحظ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعورًا بالضعف أو نقص الطاقة أو الإصابة بتقلصات عضلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعالًا.</p><p dir="RTL"><strong>غير معروفة</strong> (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إِسْهال.</p><p dir="RTL"><strong>الآثار الجانبية الإضافية في الأطفال والمراهقين</strong></p><p dir="RTL">في الأطفال الذين يُعالجون من ارتفاع ضغط الدَّم، تبدو الآثار الجانبية مماثلة لتلك التي لوحظت في البالغين، ولكنها تحدث بصورة أكثر تكرارًا. يُعَد التهاب الحَلْق أثرًا جانبيًّا شائعًا جدًّا في الأطفال ولكن لم يتم الإبلاغ عن حدوثه في فئة البالغين، وكذلك سيلان الأنف والحُمّى وارتفاع معدل ضربات القلب تُعَد آثارًا جانبية شائعة في الأطفال ولكن لم يتم الإبلاغ عن حدوثها في فئة البالغين.</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى الطبيب أو الصيدلي الخاص بك. بما في ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة. من خلال إبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">يُحفَظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة والشريط بعد كلمة &ldquo;EXP&rdquo;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">يجب التَّخزين داخل العبوة الأصلية للحماية من الرطوبة.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعد تستخدمها. سوف تُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي كانديسارتان سيليكسيتيل.</p><p dir="RTL">يحتوي كل قرص على 16 مجم كانديسارتان سيليكسيتيل.</p><p dir="RTL">المُكوِّنات الأخرى هي لاكتوز أحادي الهيدرات، نشا (الذرة)، بوفيدون &quot;K30&quot;، كاراجينان، كروسكارميلوز الصوديوم، ستيرات الماغنسيوم، أكسيد الحديد الأحمر (E 172) وأكسيد الحديد الأصفر (E 171).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قرص.</p><p dir="RTL">أقراص 16 مجم: قرص وردي مزركش مستدير وثنائي التحدُّب، محفور على أحد وجهيه &quot;16&quot; ويوجد على الوجه الآخر خط تقسيم.</p><p dir="RTL"><strong>أحجام العبوة</strong><strong>:</strong></p><p dir="RTL">عبوة شرائط من الألومنيوم/ الألومنيوم.</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة ساندوز المحدودة 10، 6250 كوندل، النمسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            07/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                DICERAN 8 mg and 16 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 8 mg of candesartan cilexetil. Excipients with known effect
Each tablet contains 66.09 mg lactose (as monohydrate) and up to 0.003 mg (0.0001 mmol) sodium. Each tablet contains 16 mg of candesartan cilexetil. Excipients with known effect
Each tablet contains 132.18 mg lactose (as monohydrate) and up to 0.006 mg (0.0003 mmol) sodium. For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.
8 mg tablets:
Pink, mottled, round biconvex tablet, debossed with 8 on one side and scored on the other side.
16 mg tablets:
Pink, mottled, round biconvex tablet, debossed with 16 on one side and scored on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>DICERAN is indicated for the:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of essential hypertension in adults</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of hypertension in children and adolescents aged 6 to &lt; 18 years.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The treatment of adult patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction  40%) when Angiotensin Converting Enzyme ( ACE)-inhibitors are not tolerated or as add-on therapy to ACE-inhibitors in patients with symptomatic heart failure, despite optimal therapy, when mineralocorticoid receptor antagonists are not tolerated (see sections 4.2, 4.4, 4.5 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology in hypertension</u></p><p>The recommended initial dose and usual maintenance dose of DICERAN is 8 mg once daily. Most of the antihypertensive effect is attained within 4 weeks. In some patients whose blood pressure is not adequately controlled, the dose can be increased to 16 mg once daily and to a maximum of 32 mg once daily. Therapy should be adjusted according to blood pressure response. DICERAN may also be administered with other antihypertensive agents (see sections 4.3, 4.4, 4.5 and 5.1). Addition of hydrochlorothiazide has been shown to have an additive antihypertensive effect with various doses of DICERAN.</p><p><em>Elderly</em></p><p>No initial dose adjustment is necessary in elderly patients.</p><p><em>Patients with intravascular volume depletion</em></p><p>An initial dose of 4 mg may be considered in patients at risk for hypotension, such as patients with possible volume depletion (see section 4.4).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>The starting dose is 4 mg in patients with renal impairment, including patients on haemodialysis. The dose should be titrated according to response. There is limited experience in patients with very severe or end- stage renal impairment (Clcreatinine &lt;15 ml/min) (see section 4.4).</p><p><em>Hepatic impairment</em></p><p>An initial dose of 4 mg once daily is recommended in patients with mild to moderate hepatic impairment. The dose may be adjusted according to response. DICERAN is contraindicated in patients with severe hepatic impairment and/or cholestasis (see sections 4.3 and 5.2).</p><p><em>Black patients</em></p><p>The antihypertensive effect of candesartan is less pronounced in black patients than in non-black patients. Consequently, up-titration of DICERAN and concomitant therapy may be more frequently needed for blood pressure control in black patients than in non-black patients (see section 5.1).</p><p><em>Paediatric population</em></p><p>Children and adolescents aged 6 to &lt;18 years:</p><p>The recommended starting dose is 4 mg once daily.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients weighing &lt; 50 kg: In patients whose blood pressure is not adequately controlled, the dose can be increased to a maximum of 8 mg once daily.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients weighing &ge; 50 kg: In patients whose blood pressure is not adequately controlled, the</p><p>dose can be increased to 8 mg once daily and then to 16 mg once daily if needed (see section 5.1).</p><p>Doses above 32 mg have not been studied in paediatric patients. Most of the antihypertensive effect is attained within 4 weeks.</p><p>For children with possible intravascular volume depletion (e.g., patients treated with diuretics, particularly those with impaired renal function), DICERAN treatment should be initiated under close medical supervision and a lower starting dose than the general starting dose above should be considered (see section 4.4).</p><p>Candesartan has not been studied in children with glomerular filtration rate less than 30 ml/min/1.73m2 (see section 4.4).</p><p>Black paediatric patients</p><p>The antihypertensive effect of candesartan is less pronounced in black patients than in non-black patients (see section 5.1).</p><p>Children aged below 1 year to &lt;6 years</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The safety and efficacy in children aged 1 to &lt;6 years of age has not been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DICERAN is contraindicated in children aged below 1 year (see section 4.3). <u>Posology in heart failure</u></p><p>The usual recommended initial dose of DICERAN is 4 mg once daily. Up-titration to the target dose of 32 mg once daily (maximum dose) or the highest tolerated dose is done by doubling the dose at intervals of at least 2 weeks (see section 4.4). Evaluation of patients with heart failure should always comprise assessment of renal function including monitoring of serum creatinine and potassium.</p><p>DICERAN can be administered with other heart failure treatment, including ACE- inhibitors, beta-blockers, diuretics and digitalis or a combination of these medicinal products. DICERAN may be co-administered with an ACE-inhibitor in patients with symptomatic heart failure despite optimal standard heart failure therapy when mineralocorticoid receptor antagonists are not tolerated. The combination of an ACE-inhibitor, a potassium-sparing diuretic and DICERAN is not recommended and should be considered only after careful evaluation of the potential benefits and risks (see sections 4.4, 4.8 and 5.1).</p><p>&nbsp;</p><p><em>Special patient populations</em></p><p>No initial dose adjustment is necessary for elderly patients or in patients with intravascular volume depletion, renal impairment or mild to moderate hepatic impairment.</p><p><u>Paediatric population</u></p><p>The safety and efficacy of DICERAN in children aged between birth and 18 years have not been established in the treatment of heart failure. No data are available.</p><p><u>Method of administration </u>Oral use.</p><p>DICERAN should be taken once daily with or without food. The bioavailability of candesartan is not affected by food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to candesartan cilexetil or to any of the excipients listed in section 6.1.
•	Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
•	Severe hepatic impairment and/or cholestasis.
•	The concomitant use of DICERAN with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
•	Children aged below 1 year (see section 5.3).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Renal impairment</u></em></p><p>As with other agents inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible patients treated with DICERAN.</p><p>When DICERAN is used in hypertensive patients with renal impairment, periodic monitoring of serum potassium and creatinine levels is recommended. There is limited experience in patients with very severe or end-stage renal impairment (Clcreatinine &lt; 15 ml/min). In these patients DICERAN should be carefully titrated with thorough monitoring of blood pressure.</p><p>Evaluation of patients with heart failure should include periodic assessments of renal function, especially in elderly patients 75 years or older, and patients with impaired renal function. During dose titration of DICERAN, monitoring of serum creatinine and potassium is recommended. Clinical trials in heart failure did not include patients with serum creatinine &gt;265 &mu;mol/L (&gt; 3 mg/dL).</p><p><em><u>Concomitant therapy with an ACE-inhibitor in heart failure</u></em></p><p>The risk of adverse reactions, especially hypotension, hyperkalaemia and decreased renal function (including acute renal failure), may increase when DICERAN is used in combination with an ACE inhibitor (see section 4.8). Triple combination of an ACE-inhibitor, a mineralocorticoid receptor antagonist and candesartan is also not recommended. Use of these combinations should be under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>&nbsp;</p><p>&nbsp;</p><p>ACE inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><em><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></em></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1). If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>&nbsp;</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><em><u>Haemodialysis</u></em></p><p>During dialysis the blood pressure may be particularly sensitive to AT1-receptor blockade as a result of reduced plasma volume and activation of the renin-angiotensin-aldosterone system. Therefore DICERAN should be carefully titrated with thorough monitoring of blood pressure in patients on haemodialysis.</p><p><em><u>Renal artery stenosis</u></em></p><p>Medicinal products that affect the renin-angiotensin-aldosterone system, including angiotensin II receptor antagonists (AIIRAs), may increase blood urea and serum creatinine in patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney.</p><p><em><u>Kidney transplantation</u></em></p><p>There is limited clinical evidence regarding DICERAN use in patients who have undergone renal transplant.</p><p><em><u>Hypotension</u></em></p><p>Hypotension may occur during treatment with DICERAN in heart failure patients. It may also occur in hypertensive patients with intravascular volume depletion such as those receiving high dose diuretics.</p><p>Caution should be observed when initiating therapy and correction of hypovolemia should be attempted.</p><p><em><u>Anaesthesia and surgery</u></em></p><p>Hypotension may occur during anaesthesia and surgery in patients treated with angiotensin II antagonists due to blockade of the renin-angiotensin system. Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors.</p><p><em><u>Aortic and mitral valve stenosis (obstructive hypertrophic cardiomyopathy)</u></em></p><p>As with other vasodilators, special caution is indicated in patients suffering from haemodynamically relevant aortic or mitral valve stenosis, or obstructive hypertrophic cardiomyopathy.</p><p><em><u>Primary hyperaldosteronism</u></em></p><p>Patients with primary hyperaldosteronism will not generally respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin-aldosterone system. Therefore, the use of DICERAN is not recommended in this population.</p><p><em><u>Hyperkalaemia</u></em></p><p>Concomitant use of DICERAN with potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products that may increase potassium levels (e.g. heparin, co- trimoxazole also known as trimethoprim/sulfamethoxazole) may lead to increases in serum potassium in hypertensive patients. Monitoring of potassium should be undertaken as appropriate.</p><p>In heart failure patients treated with DICERAN, hyperkalaemia may occur. Periodic monitoring of serum potassium is recommended.</p><p>The combination of an ACE inhibitor, a potassium-sparing diuretic (e.g. spironolactone) and DICERAN is not recommended and should be considered only after careful evaluation of the potential benefits and risks.</p><p><em><u>General</u></em></p><p>In patients whose vascular tone and renal function depend predominantly on the activity of the renin- angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with other medicinal products that affect this system has been associated with acute hypotension, azotaemia, oliguria or, rarely, acute renal failure. The possibility of similar effects cannot be excluded with AIIRAs. As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or ischaemic cerebrovascular disease could result in a myocardial infarction or stroke.</p><p>The antihypertensive effect of candesartan may be enhanced by other medicinal products with blood pressure lowering properties, whether prescribed as an antihypertensive or prescribed for other indications.</p><p>&nbsp;</p><p><em><u>Pregnancy</u></em></p><p>Angiotensin II antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p>In post-menarche patients the possibility of pregnancy should be evaluated on a regular basis. Appropriate information should be given and/or action taken to prevent the risk of exposure during pregnancy (see sections 4.3 and 4.6).</p><p><em><u>Use in paediatric patients, including patients with renal impairment</u></em></p><p>Candesartan has not been studied in children with a glomerular filtration rate less than 30 ml/min/1.73m2 (see section 4.2).</p><p>For children with possible intravascular volume depletion (e.g. patients treated with diuretics, particularly those with impaired renal function), DICERAN treatment should be initiated under close medical supervision and a lower starting dose should be considered (see section 4.2).</p><p><em><u>Special warnings regarding excipients</u></em></p><p>This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Compounds which have been investigated in clinical pharmacokinetic studies include hydrochlorothiazide, warfarin, digoxin, oral contraceptives (i.e. ethinylestradiol/levonorgestrel), glibenclamide, nifedipine and enalapril. No clinically significant pharmacokinetic interactions with these medicinal products have been identified.</p><p>Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products (e.g. heparin) may increase potassium levels. Monitoring of potassium should be undertaken as appropriate (see section 4.4).</p><p><em>Dual blockade of the RAAS with AIIRAs, ACE inhibitors, or aliskiren</em></p><p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE inhibitors, angiotensin II receptor blockers or aliskiren is</p><p>associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p>&nbsp;</p><p>&nbsp;</p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors. A similar effect may occur with AIIRAs. Use of candesartan with lithium is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p>&nbsp;</p><p>&nbsp;</p><p>When AIIRAs are administered simultaneously with non-steroidal anti-inflammatory drugs (NSAIDs) (i.e. selective COX-2 inhibitors, acetylsalicylic acid (&gt;3g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.</p><p>As with ACE inhibitors, concomitant use of AIIRAs and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Pregnancy</u></em></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:74.75pt;margin-top:9.9pt;width:463.8pt;height:39.4pt;z-index:251656704;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".6pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0in;margin-right:11.05pt;margin-bottom:
     0in;margin-left:4.95pt;margin-bottom:.0001pt;text-align:justify;
     line-height:102%'><span style='font-family:"Times New Roman",serif;
     mso-hansi-font-family:Arial;mso-bidi-font-family:Arial'>The use of AIIRAs
     is not recommended during the first trimester of pregnancy (see section
     4.4). The use of AIIRAs is contra-indicated during the second and third
     trimester of pregnancy (see section 4.3 and 4.4)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="623" height="57" alt="Text Box: The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contra-indicated during the second and third trimester of pregnancy (see section 4.3 and 4.4)" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/2/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with AIIRAs, similar risks may exist for this class of medicinal products. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately and, if appropriate, alternative therapy should be started.</p><p>&nbsp;</p><p>&nbsp;</p><p>Exposure to AIIRA therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).</p><p>Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p><em><u>Breast-feeding</u></em></p><p>Because no information is available regarding the use of DICERAN during breast- feeding, DICERAN is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of candesartan on the ability to drive and use machines have been performed. However, it should be taken into account that occasionally dizziness or weariness may occur during treatment with DICERAN.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Treatment of hypertension</u></em></p><p>In controlled clinical studies adverse reactions were mild and transient. The overall incidence of adverse events showed no association with dose or age. Withdrawals from treatment due to adverse events were similar with candesartan cilexetil (3.1%) and placebo (3.2%).</p><p>In a pooled analysis of clinical trial data of hypertensive patients, adverse reactions with candesartan cilexetil were defined based on an incidence of adverse events with candesartan cilexetil at least 1% higher than the incidence seen with placebo. By this definition, the most commonly reported adverse reactions were dizziness/vertigo, headache and respiratory infection.</p><p>The table below presents adverse reactions from clinical trials and post-marketing experience. The frequencies used in the tables throughout section 4.8 are:</p><p>very common (1/10), common (1/100 to &lt;1/10), uncommon (1/1,000 to &lt;1/100), rare (1/10,000 to</p><p>&lt;1/1,000) and very rare (&lt;1/10,000).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Undesirable Effect</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Respiratory infection</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Leukopenia, neutropenia and agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hyperkalaemia, hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness/vertigo, headache</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Hepato-biliary disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Increased liver enzymes, abnormal hepatic function or hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Angioedema, rash, urticaria, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Back pain, arthralgia, myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Renal impairment, including renal failure in susceptible patients (see section 4.4)</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Laboratory findings</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p>In general, there were no clinically important influences of candesartan cilexetil on routine laboratory variables. As for other inhibitors of the renin-angiotensin-aldosterone system, small decreases in haemoglobin have been seen. No routine monitoring of laboratory variables is usually necessary for patients receiving DICERAN. However, in patients with renal impairment, periodic monitoring of serum potassium and creatinine levels is recommended.</p><p><em><u>Paediatric population</u></em></p><p>The safety of candesartan cilexetil was monitored in 255 hypertensive children and adolescents, aged 6 to</p><p>&lt;18 years old, during a 4 week clinical efficacy study and a 1 year open label study (see section 5.1). In nearly all different system organ classes, the frequency of adverse events in children are within common/uncommon range. Whilst the nature and severity of the adverse events are similar to those in adults (see the table above), the frequency of all adverse events are higher in children and adolescents, particularly in:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache, dizziness and upper respiratory tract infection, are &ldquo;very common&rdquo; (ie, &ge;1/10) in children and common (&ge; 1/100 to &lt; 1/10) in adults.</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough is &ldquo;very common&rdquo; (ie, &gt; 1/10) in children and very rare (&lt;1/10,000) in adults.</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash is &ldquo;common&rdquo; (ie, &ge;1/100 to &lt;1/10) in children and &ldquo;very rare&rdquo; (&lt;1/10,000) in adults.</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperkalaemia, hyponatraemia and abnormal liver function are uncommon (&ge; 1/1,000 to &lt; 1/100) in</p><p>children and very rare (&lt; 1/10,000) in adults.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sinus arrhythmia, nasopharyngitis, pyrexia are &ldquo;common&rdquo; (ie, &ge;1/100 to &lt;1/10) and oropharyngeal pain is &ldquo;very common&rdquo; (ie, &ge;1/10) in children; but none are reported in adults. However these are temporary and widespread childhood illnesses.</p><p>&nbsp;</p><p>&nbsp;</p><p>The overall safety profile for candesartan cilexetil in paediatric patients does not differ significantly from the safety profile in adults.</p><p><em><u>Treatment of heart failure</u></em></p><p>The adverse experience profile of candesartan cilexetil in heart failure patients was consistent with the pharmacology of the medicinal product and the health status of the patients. In the CHARM clinical programme, comparing candesartan cilexetil in doses up to 32 mg (n=3,803) to placebo (n=3,796), 21.0% of the candesartan cilexetil group and 16.1% of the placebo group discontinued treatment because of adverse events. The most commonly reported adverse reactions were hyperkalaemia, hypotension and renal impairment. These events were more common in patients over 70 years of age, diabetics, or subjects who received other medicinal products which affect the renin- angiotensin-aldosterone system, in particular an ACE inhibitor and/or spironolactone.</p><p>The table below presents adverse reactions from clinical trials and post-marketing experience.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Undesirable Effect</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Leukopenia, neutropenia and agranulocytosis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Hyperkalaemia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Dizziness, headache</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Hepato-biliary disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Increased liver enzymes, abnormal hepatic function or hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Angioedema, rash, urticaria, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Back pain, arthralgia, myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Renal impairment, including renal failure in susceptible patients (see section 4.4)</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Laboratory findings:</em></p><p>Hyperkalaemia and renal impairment are common in patients treated with DICERA for the indication of heart failure. Periodic monitoring of serum creatinine and potassium is recommended (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Symptoms</u></em></p><p>Based on pharmacological considerations, the main manifestation of an overdose is likely to be symptomatic hypotension and dizziness. In individual case reports of overdose (of up to 672 mg candesartan cilexetil), patient recovery was uneventful.</p><p><em><u>Management</u></em></p><p>If symptomatic hypotension should occur, symptomatic treatment should be instituted and vital signs monitored. The patient should be placed supine with the legs elevated. If this is not sufficient, plasma volume should be increased by infusion of, for example, isotonic saline solution. Sympathomimetic medicinal products may be administered if the above-mentioned measures are not sufficient.</p><p>Candesartan cilexetil is not removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group:</p><p>Agents acting on the renin-angiotensin system, Angiotensin II antagonists, plain, ATC code: C09CA06. Mechanism of action</p><p>Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system and plays a role in the pathophysiology of hypertension, heart failure and other cardiovascular disorders. It also has a role in the pathogenesis of end organ hypertrophy and damage. The major physiological</p><p>effects of angiotensin II, such as vasoconstriction, aldosterone stimulation, regulation of salt and water homeostasis and stimulation of cell growth, are mediated via the type 1 (AT1) receptor.</p><p>Candesartan cilexetil is a prodrug suitable for oral use. It is rapidly converted to the active substance, candesartan, by ester hydrolysis during absorption from the gastrointestinal tract. Candesartan is an AIIRA, selective for AT1 receptors, with tight binding to and slow dissociation from the receptor. It has no agonist activity.</p><p>Pharmacodynamic effects</p><p>Candesartan does not inhibit ACE, which converts angiotensin I to angiotensin II and degrades bradykinin. There is no effect on ACE and no potentiation of bradykinin or substance P. In controlled clinical trials comparing candesartan cilexetil with ACE inhibitors, the incidence of cough was lower in patients receiving candesartan cilexetil. Candesartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation. The antagonism of the angiotensin II (AT1) receptors results in dose related increases in plasma renin levels, angiotensin I and angiotensin II levels, and a decrease in plasma aldosterone concentration.</p><p>Clinical efficacy and safety</p><p><em><u>Hypertension</u></em></p><p>&nbsp;</p><p>In hypertension, candesartan causes a dose-dependent, long-lasting reduction in arterial blood pressure. The antihypertensive action is due to decreased systemic peripheral resistance, without reflex increase in heart rate. There is no indication of serious or exaggerated first dose hypotension or rebound effect after cessation of treatment.</p><p>After administration of a single dose of candesartan cilexetil, onset of antihypertensive effect generally occurs within 2 hours. With continuous treatment, most of the reduction in blood pressure with any dose is generally attained within four weeks and is sustained during long-term treatment. According to a meta- analysis, the average additional effect of a dose increase from 16 mg to 32 mg once daily was small.</p><p>Taking into account the inter-individual variability, a more than average effect can be expected in some patients. Candesartan cilexetil once daily provides effective and smooth blood pressure reduction over 24 hours with little difference between maximum and trough effects during the dosing interval. The antihypertensive effect and tolerability of candesartan and losartan were compared in two randomised, double-blind studies in a total of 1,268 patients with mild to moderate hypertension. The trough blood pressure reduction (systolic/diastolic) was 13.1/10.5 mmHg with candesartan cilexetil 32 mg once daily and 10.0/8.7 mmHg with losartan potassium 100 mg once daily (difference in blood pressure reduction 3.1/1.8 mmHg, p&lt;0.0001/p&lt;0.0001).</p><p>When candesartan cilexetil is used together with hydrochlorothiazide, the reduction in blood pressure is additive. An increased antihypertensive effect is also seen when candesartan cilexetil is combined with amlodipine or felodipine.</p><p>Medicinal products that block the renin-angiotensin-aldosterone system have less pronounced antihypertensive effect in black patients (usually a low-renin population) than in non-black patients. This is also the case for candesartan. In an open-label clinical experience trial in 5,156 patients with diastolic hypertension, the blood pressure reduction during candesartan treatment was significantly less in black than non-black patients (14.4/10.3 mmHg vs 19.0/12.7 mmHg, p&lt;0.0001/p&lt;0.0001)</p><p>&nbsp;</p><p>&nbsp;</p><p>Candesartan increases renal blood flow and either has no effect on or increases glomerular filtration rate while renal vascular resistance and filtration fraction are reduced. In a 3-month clinical study in hypertensive patients with type 2 diabetes mellitus and microalbuminuria, antihypertensive treatment with candesartan cilexetil reduced urinary albumin excretion (albumin/creatinine ratio, mean 30%, 95% CI 15- 42%). There is currently no data on the effect of candesartan on the progression to diabetic nephropathy.</p><p>&nbsp;</p><p>&nbsp;</p><p>The effects of candesartan cilexetil 8-16 mg (mean dose 12 mg), once daily, on cardiovascular morbidity and mortality were evaluated in a randomised clinical trial with 4,937 elderly patients (aged 70-89 years; 21% aged 80 or above) with mild to moderate hypertension followed for a mean of 3.7 years (Study on Cognition and Prognosis in the Elderly). Patients received candesartan cilexetil or placebo with other antihypertensive treatment added as needed. The blood pressure was reduced from 166/90 to 145/80 mmHg in the candesartan cilexetil group, and from 167/90 to 149/82 mmHg in the control group. There was no statistically significant difference in the primary endpoint, major cardiovascular events (cardiovascular mortality, non-fatal stroke and non-fatal myocardial infarction). There were 26.7 events per 1000 patient- years in the candesartan group versus 30.0 events per 1000 patient-years in the control group (relative risk 0.89, 95% CI 0.75 to 1.06, p=0.19).</p><p><em><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></em></p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON- D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>&nbsp;</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The antihypertensive effects of candesartan were evaluated in hypertensive children aged 1 to &lt;6 years and 6 to &lt;17 years in two randomised, double-blind multicentre, 4 week dose ranging studies.</p><p>&nbsp;</p><p>&nbsp;</p><p>In children aged 1 to &lt;6 years, 93 patients, 74% of whom had renal disease, were randomized to receive an oral dose of candesartan cilexetil suspension 0.05, 0.20 or 0.40 mg/kg once daily.</p><p>The primary method of analysis was slope of the change in systolic blood pressure (SBP) as a function of dose. SBP and diastolic blood pressure (DBP) decreased 6.0/5.2 to 12.0/11.1 mmHg from baseline across the three doses of candesartan cilexetil. However, since there was no placebo group, the true magnitude of blood pressure effect remains uncertain which makes a conclusive assessment of benefit-risk balance difficult in this age group.</p><p>&nbsp;</p><p>&nbsp;</p><p>In children aged 6 to &lt;17 years, 240 patients were randomised to receive either placebo or low, medium, or high doses of candesartan cilexetil in a ratio of 1: 2: 2: 2. For children who weighed &lt; 50 kg, the doses of candesartan cilexetil were 2, 8, or 16 mg once daily. In children who weighed &gt; 50 kg, the candesartan cilexetil doses were 4, 16 or 32 mg once daily. Candesartan at pooled doses reduced SiSBP by 10.2 mmHg (P&lt; 0.0001) and SiDBP (P=0.0029) by 6.6 mmHg, from the base line. In the placebo group, there was also a reduction of 3.7 mmHg in SiSBP (p=0.0074) and 1.80 mmHg for SiDBP (p=0.0992) from the baseline. Despite the large placebo effect, all individual candesartan doses (and all doses pooled) were significantly superior to placebo. Maximum response in reduction of blood pressure in children below and above 50 kg was reached at 8 mg and 16 mg doses, respectively and the effect plateaued after that point.</p><p>Of those enrolled, 47% were black patients and 29% were female; mean age +/- SD was 12.9 +/- 2.6 years. In children aged 6 to &lt; 17 years there was a trend for a lesser effect on blood pressure in black patients compared to non-black patients.</p><p><em><u>Heart failure</u></em></p><p>Treatment with candesartan cilexetil reduces mortality, reduces hospitalisation due to heart failure and improves symptoms in patients with left ventricular systolic dysfunction as shown in the Candesartan in Heart failure &ndash; Assessment of Reduction in Mortality and morbidity (CHARM) programme.</p><p>This placebo controlled, double-blind study programme in chronic heart failure (CHF) patients with NYHA functional class II to IV consisted of three separate studies: CHARM-Alternative (n=2,028) in patients with LVEF &le;40% not treated with an ACE inhibitor because of intolerance (mainly due to cough, 72%), CHARM- Added (n=2,548) in patients with LVEF &le; 40% and treated with an ACE inhibitor, and CHARM-Preserved (n=3,023) in patients with LVEF&gt;40%. Patients on optimal CHF therapy at baseline were randomised to placebo or candesartan cilexetil (titrated from 4 mg or 8 mg once daily to 32 mg once daily or the highest tolerated dose, mean dose 24 mg) and followed for a median of 37.7 months. After 6 months of treatment 63% of the patients still taking candesartan cilexetil (89%) were at the target dose of 32 mg.</p><p>In CHARM-Alternative, the composite endpoint of cardiovascular mortality or first CHF hospitalisation was significantly reduced with candesartan in comparison with placebo, hazard ratio (HR) 0.77 (95% CI 0.67- 0.89, p&lt;0.001). This corresponds to a relative risk reduction of 23%. Of candesartan patients 33.0% (95%CI: 30.1 to 36.0) and of placebo patients 40.0% (95%CI: 37.0 to</p><p>43.1) experienced this endpoint, absolute difference 7.0% (95%CI: 11.2 to 2.8). Fourteen patients needed to be treated for the duration of the study to prevent one patient from dying of</p><p>&nbsp;</p><p>cardiovascular event or being hospitalised for treatment of heart failure. The composite endpoint of all- cause mortality or first CHF hospitalisation was also significantly reduced with candesartan HR 0.80(95%CI: 0.70-0.92, p=0.001). Of candesartan patients 36.6% (95%CI: 33.7 to 39.7) and of</p><p>placebo patients 42.7% (95%CI: 39.6 to 45.8) experienced this endpoint, absolute difference 6.0%</p><p>(95%CI: 10.3 to 1.8).</p><p>Both the mortality and morbidity (CHF hospitalisation) components of these composite endpoints contributed to the favourable effects of candesartan. Treatment with candesartan cilexetil resulted in improved NYHA functional class (p=0.008).</p><p>&nbsp;</p><p>&nbsp;</p><p>In CHARM-Added, the composite endpoint of cardiovascular mortality or first CHF hospitalisation was significantly reduced with candesartan in comparison with placebo, HR 0.85(95%CI: 0.75-0.96, p=0.011). This corresponds to a relative risk reduction of 15%. Of candesartan patients 37.9% (95%CI: 35.2 to 40.6) and of placebo patients 42.3% (95%CI: 39.6 to 45.1) experienced this endpoint, absolute difference 4.4% (95%CI: 8.2 to 0.6). Twenty-three patients needed to be treated for the duration of the study to prevent one patient from dying of a cardiovascular event or being hospitalised for treatment of heart failure. The composite endpoint of all-cause mortality or first CHF hospitalisation was also significantly reduced with candesartan, HR 0.87(95%CI: 0.78-0.98, p=0.021). Of candesartan patients 42.2% (95%CI: 39.5 to 45.0) and of placebo patients 46.1% (95%CI: 43.4 to 48.9) experienced this endpoint, absolute difference 3.9% (95%CI: 7.8 to 0.1). Both the mortality and morbidity components of these composite endpoints contributed to the favourable effects of candesartan. Treatment with candesartan cilexetil resulted in improved NYHA functional class (p=0.020).</p><p>In CHARM-Preserved, no statistically significant reduction was achieved in the composite endpoint of cardiovascular mortality or first CHF hospitalisation, HR 0.89(95%CI: 0.77 to 1.03, p=0.118).</p><p>All-cause mortality was not statistically significant when examined separately in each of the three CHARM studies. However, all-cause mortality was also assessed in pooled populations, CHARM- Alternative and CHARM-Added, HR 0.88(95%CI: 0.79-0.98, p=0.018) and all three studies, HR 0.91(95%CI: 0.83 to 1.00, p=0.055).</p><p>The beneficial effects of candesartan were consistent irrespective of age, gender and concomitant medicinal product. Candesartan was effective also in patients taking both beta-blockers and ACE inhibitors at the same time, and the benefit was obtained whether or not patients were taking ACE inhibitors at the target dose recommended by treatment guidelines.</p><p>In patients with CHF and depressed left ventricular systolic function (left ventricular ejection fraction, LVEF</p><p>&le; 40%), candesartan decreases systemic vascular resistance and pulmonary capillary wedge pressure,</p><p>increases plasma renin activity and angiotensin II concentration, and decreases aldosterone levels</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Absorption and distribution</u></em></p><p>Following oral administration, candesartan cilexetil is converted to the active substance candesartan. The absolute bioavailability of candesartan is approximately 40% after an oral solution of candesartan cilexetil. The relative bioavailability of the tablet formulation compared with the same oral solution is approximately 34% with very little variability. The estimated absolute bioavailability of the tablet is therefore 14%. The mean peak serum concentration (Cmax) is reached 3-4 hours following tablet intake. The candesartan serum concentrations increase linearly with increasing doses in the therapeutic dose range. No gender related differences in the pharmacokinetics of candesartan have been observed. The area under the serum concentration versus time curve (AUC) of candesartan is not significantly affected by food.</p><p>Candesartan is highly bound to plasma protein (more than 99%). The apparent volume of distribution of candesartan is 0.1 l/kg.</p><p>The bioavailability of candesartan is not affected by food.</p><p><em><u>Biotransformation and elimination</u></em></p><p>Candesartan is mainly eliminated unchanged via urine and bile and only to a minor extent eliminated by hepatic metabolism (CYP2C9). Available interaction studies indicate no effect on CYP2C9 and CYP3A4.</p><p>&nbsp;</p><p>Based on <em>in vitro </em>data, no interaction would be expected to occur <em>in vivo </em>with medicinal products whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4. The terminal half-life of candesartan is approximately 9 hours. There is no accumulation following multiple doses.</p><p>&nbsp;</p><p>&nbsp;</p><p>Total plasma clearance of candesartan is about 0.37 ml/min/kg, with a renal clearance of about 0.19 ml/min/kg. The renal elimination of candesartan is both by glomerular filtration and active tubular secretion. Following an oral dose of 14C-labelled candesartan cilexetil, approximately 26% of the dose is excreted in the urine as candesartan and 7% as an inactive metabolite while approximately 56% of the dose is recovered in the faeces as candesartan and 10% as the inactive metabolite.</p><p><em><u>Pharmacokinetics in special populations</u></em></p><p>In the elderly (over 65 years) Cmax and AUC of candesartan are increased by approximately 50% and 80%, respectively in comparison to young subjects. However, the blood pressure response and the incidence of adverse events are similar after a given dose of DICERAN in young and elderly patients (see section 4.2).</p><p>In patients with mild to moderate renal impairment Cmax and AUC of candesartan increased during repeated dosing by approximately 50% and 70%, respectively, but t1/2 was not altered, compared to patients with normal renal function. The corresponding changes in patients with severe renal impairment were approximately 50% and 110%, respectively. The terminal t1/2 of candesartan was approximately doubled in patients with severe renal impairment. The AUC of candesartan in patients undergoing haemodialysis was similar to that in patients with severe renal impairment.</p><p>&nbsp;</p><p>&nbsp;</p><p>In two studies, both including patients with mild to moderate hepatic impairment, there was an increase in the mean AUC of candesartan of approximately 20% in one study and 80% in the other study (see section 4.2). There is no experience in patients with severe hepatic impairment.</p><p><em>Paediatric population</em></p><p>The pharmacokinetic properties of candesartan were evaluated in hypertensive children aged 1 to &lt;6 years and 6 to &lt;17 years in two single dose PK studies.</p><p>In children aged 1 to &lt;6 years, 10 children weighing 10 to &lt;25 kg received a single dose of 0.2 mg/kg, oral suspension. There was no correlation between Cmax and AUC with age or weight.</p><p>No clearance data has been collected; therefore the possibility of a correlation between clearance and weight/age in this population is unknown.</p><p>In children aged 6 to &lt;17 years, 22 children received a single dose of 16 mg tablet. There was no correlation between Cmax and AUC with age. However weight seems to significantly correlate with Cmax (p=0.012) and AUC (p=0.011). No clearance data, has been collected, therefore the possibility of a correlation between clearance and weight/age in this population is unknown.</p><p>Children &gt;6 years of age had exposure similar to adults given the same dose.</p><p>The pharmacokinetics of candesartan cilexetil have not been investigated in paediatric patients &lt;1 year of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In preclinical safety studies candesartan had effects on the kidneys and on red cell parameters at high doses in mice, rats, dogs and monkeys. Candesartan caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). Effects on the kidneys (such as interstitial nephritis, tubular distension, basophilic tubules; increased plasma concentrations of urea and creatinine) were induced by candesartan which could be secondary to the hypotensive effect leading to alterations of renal perfusion. Furthermore, candesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells. These changes were considered to be caused by the pharmacological action of candesartan. For therapeutic doses of candesartan in humans, the hyperplasia/hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.</p><p>Foetotoxicity has been observed in late pregnancy (see section 4.6).</p><p>&nbsp;</p><p>In preclinical studies in normotensive neonatal and juvenile rats, candesartan caused a reduction in body weight and heart weight. As in adult animals, these effects are considered to result from the pharmacological action of candesartan. At the lowest dose of 10 mg/kg exposure to candesartan was between 12 and 78 times the levels found in children aged 1 to &lt;6 who received candesartan cilexetil at a dose of 0.2 mg/kg and 7 to 54 times those found in children aged 6 to &lt;17 who received candesartan cilexetil at a dose of 16 mg. As a no observed effect level was not identified in these</p><p>&nbsp;</p><p>&nbsp;</p><p>studies, the safety margin for the effects on heart weight and the clinical relevance of the finding is unknown.</p><p>Data from <em>in vitro </em>and <em>in vivo </em>mutagenicity testing indicate that candesartan will not exert mutagenic or clastogenic activities under conditions of clinical use.</p><p>There was no evidence of carcinogenicity.</p><p>The renin-angiotensin-aldosterone system plays a critical role in kidney development in utero. Renin- angiotensin-aldosterone system blockade has been shown to lead to abnormal kidney development in very young mice. Administering medicinal products that act directly on the renin-angiotensin- aldosterone system can alter normal renal development. Therefore, children aged less than 1 year should not receive DICERAN (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate Maize starch Povidone K30 Carrageenan Croscarmellose sodium Magnesium stearate</p><p>Ferric oxide, red (E 172) (only for 8, 16 and 32 mg tablets) Titanium dioxide (E 171) (only for 8, 16 and 32 mg tablets)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
Storage conditions after first opening of the bottle:
Store in the original package in order to protect from moisture.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package in order to protect from moisture. Store below 30˚C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>8 mg and 16 mg tablets:</em></p><p>Al/Al Blister pack.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sandoz GmbH, 10, 6250 Kundl, Austria
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>